The expansion of polyclonal T regulatory cells (Tregs) offers great promise for the treatment
of immune-mediated diseases, such as multiple sclerosis (MS). However, polyclonal Tregs
can be non-specifically immunosuppressive. Based on the advancements with chimeric
antigen receptor (CAR) therapy in leukemia, we previously engineered Tregs to express a T-
cell receptor (TCR) specific for a myelin basic protein (MBP) peptide. These TCR-
engineered specific Tregs suppressed the proliferation of MBP-reactive T effector cells and …